Cortexin

Cortexin is a manufactured mixture of polypeptides extracted from young cattle or pig cerebral cortex, a Russian “peptide bioregulator” drug conceptually similar to Cerebrolysin. Its human trial record is small, entirely Russian-language, and tested it delivered by nasal electrophoresis or combined with a breathing-exercise program, not as a plain intramuscular injection tested alone against a placebo. It has no FDA or EMA approval and is registered only in Russia and neighbouring states.

Ask about Cortexin

Research snapshot

Peptide categoryManufactured mixture of low-molecular-weight polypeptides (bovine/porcine cerebral cortex extract), Russian “peptide bioregulator”
Primary research interestCognitive and functional support in cerebrovascular insufficiency and aging
Highest available evidenceSmall human comparative/observational trials, published only in Russian
Human research availableYes, limited: two small Russian studies, neither testing a standalone intramuscular dose against placebo
Development statusMarketed prescription drug in Russia and neighboring states; no Western clinical development program identified
Regulatory statusRegistered as a prescription drug in Russia and neighbouring states; not approved in the US, EU, or other major jurisdictions

Technical identity

Primary nameCortexin
Alternative namesCortexine (brand variant), Kortexin (misspelling), cortical peptide bioregulator
Peptide sequenceNot applicable: a manufactured mixture of multiple polypeptides, not a single defined sequence
Amino-acid lengthNot applicable: heterogeneous mixture
Molecular formulaNot applicable: heterogeneous mixture, no single formula
Molecular weightDescribed by the manufacturer as low-molecular-weight polypeptides; no single verifiable figure
CAS Registry NumberNot established for a mixture product
PubChem CIDNot applicable
UNIINot reliably established
DrugBank IDNot listed
Chemical modificationsNot applicable: a manufactured tissue-extract mixture rather than a single synthesized/modified peptide
Peptide classTissue-derived peptide bioregulator (conceptually similar to Cerebrolysin)
Primary biological targetDescribed by the manufacturer as tissue-specific rather than acting through one identified receptor
Developer or originatorVladimir Khavinson’s research group (Russia)
Development statusMarketed (Russia and neighboring states)

What it is

Cortexin is a manufactured mixture of low-molecular-weight polypeptides extracted from the cerebral cortex of young cattle or pigs, developed in Russia by Vladimir Khavinson’s group and sold there as a registered prescription “peptide bioregulator” drug, typically as a lyophilized powder for intramuscular injection. Like Cerebrolysin, it is a biological mixture rather than a single defined peptide, and its manufacturer describes it as tissue-specific rather than acting through one identified receptor.

It has never been submitted for approval in the United States, the European Union or any other major regulatory jurisdiction outside the countries where Khavinson-group bioregulators circulate (principally Russia and some neighbouring states), and it has no FDA label or EMA authorisation.

Potential benefits and research applications

Cognitive and functional improvement in chronic cerebrovascular insufficiency

A 1999 Russian trial in 76 patients with a Russian diagnostic category roughly corresponding to chronic cerebrovascular insufficiency reported improved psychoemotional state, attention, memory and EEG measures when Cortexin was added to standard therapy, delivered by nasal electrophoresis rather than injection.

Evidence: has been reported in one human comparative trial (Tier 2, human observational/comparative evidence); the delivery method (electrophoresis) does not match how the drug is typically administered or how it circulates in research-peptide use, so this finding cannot be attributed to a standard injection.

Functional and professional performance in older adults, tested only as part of a combined intervention

A 2020 study in elderly university teachers combined breathing exercises with Cortexin and reported improved professional performance and functional state lasting up to two months. The study was explicitly framed as testing the combination, not Cortexin alone.

Evidence: has been reported in one human combination-intervention study (Tier 2, human observational evidence, combination design); has not been established for Cortexin given by itself.

The human trial record

A 1999 trial in 76 patients with stage I-II dyscirculatory encephalopathy (a Russian diagnostic category roughly corresponding to chronic cerebrovascular insufficiency) compared standard therapy alone (31 patients) against standard therapy plus adjuvant Cortexin delivered by nasal electrophoresis (45 patients), reporting improvement in psychoemotional state, attention, memory and EEG measures in the Cortexin group, described as a randomized comparative clinical trial in its own indexing.

A 2020 study in elderly university teachers combined breathing exercises with the Cortexin peptide bioregulator and reported improved measures of professional performance and functional state over two weeks, with the benefit lasting up to two months; this was framed as testing a combination intervention (breathing exercises plus Cortexin) rather than Cortexin alone.

Every trial located for this entry was published in Russian, conducted at Russian institutions, and used a delivery method, either nasal electrophoresis or combination with a behavioural intervention, that does not correspond to a simple systemic injection. No trial located for this entry reports a straightforward intramuscular dose in milligrams tested against a placebo in isolation, and no trial appears on ClinicalTrials.gov.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. No trial located for this entry tested a standalone intramuscular dose against placebo in isolation from its delivery method or a co-intervention.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Chronic cerebrovascular insufficiency (dyscirculatory encephalopathy)Nasal electrophoresis (not standard injection)Not independently re-extracted for this pageNot specifiedNot specifiedPublished human comparative trial (Khavinson et al., 1999)
Functional/professional performance in elderly adults (combined with breathing exercises)Not specified for Cortexin alone (combination intervention)Not independently re-extracted for this pageNot specifiedBenefit reported lasting up to 2 monthsPublished human combination-intervention study (Lysenko et al., 2020)
Cognitive/neuroprotective support, general (commercial/community use)Intramuscular10 mg per doseOnce daily10-day courseMatches the standard commercial Russian product’s labelled use; not the exact regimen tested against placebo in either trial reviewed

What is not known

Whether Cortexin given alone, by standard intramuscular injection, produces the effects reported when it was delivered by nasal electrophoresis or combined with breathing exercises. No trial located for this entry isolated the drug from its delivery method or its co-intervention.

Whether these results would replicate in a blinded, placebo-controlled Western trial. None was located.

Long-term human safety data outside these small Russian studies.

Frequently asked questions

What is Cortexin?

Cortexin is a manufactured mixture of low-molecular-weight polypeptides extracted from young cattle or pig cerebral cortex, sold in Russia as a registered prescription bioregulator drug.

How does Cortexin work?

It is described by its manufacturer as tissue-specific rather than acting through one identified receptor, similar in concept to Cerebrolysin. Its exact mechanism has not been isolated to a single active component in the sources reviewed for this entry.

What dosage has been studied in humans?

The trials located for this entry did not test a standalone intramuscular dose against placebo. One delivered it via nasal electrophoresis; the other combined it with a breathing-exercise program.

What dosage commonly circulates online?

Circulating material describes 10 milligrams intramuscularly, once daily, over a 10-day course, matching the standard commercial Russian product’s labelled use. Neither trial reviewed for this entry tested that exact regimen alone against a placebo.

Has Cortexin been studied in humans?

Yes, in two small Russian studies, but neither isolated a plain intramuscular dose from its delivery method or a co-intervention, and neither appears on ClinicalTrials.gov.

Is Cortexin approved for use?

It is registered as a prescription drug in Russia and some neighbouring states. It has no FDA or EMA approval.

What routes of administration are reported?

The commercial product is intramuscular. The trials reviewed for this entry used nasal electrophoresis or combined the drug with a non-drug intervention.

Does Cortexin work when given alone by injection?

This has not been established. No trial located for this entry tested a standalone intramuscular dose against placebo in isolation from its delivery method or a co-intervention.

What side effects have been reported?

No detailed adverse-event profile was reported in the small Russian trials reviewed for this entry, and no modern Western safety study was located.

What remains unknown about Cortexin?

Whether it produces the reported effects when given alone by standard injection rather than by electrophoresis or combined with another intervention; whether these results would replicate in a blinded, Western-standard trial; and its long-term human safety profile.

Bottom line

Cortexin is a Russian brain-tissue-derived peptide mixture with a genuine but narrow human trial record, two small studies, both published only in Russian, neither testing the drug as a standalone injection against placebo. One delivered it by nasal electrophoresis and the other combined it with a breathing-exercise program, so neither cleanly isolates Cortexin’s own effect. It remains registered only in Russia and neighbouring states, with no FDA or EMA approval.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Cognitive/neuroprotective support, generalIntramuscular10 mg per doseOnce daily10 day course

Circulating material for Cortexin describes a 10 mg intramuscular dose, once daily, over a 10 day course, which matches the standard commercial Russian product's labelled use rather than a figure invented for the research-peptide market. But neither trial reviewed for this entry tested that exact regimen against a placebo in isolation: one delivered the drug via nasal electrophoresis and the other combined it with a breathing-exercise programme. A plain intramuscular course has not, on the sources reviewed here, been tested alone against a placebo.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Research area: Neuro and cognitive.

Share thisFacebookXEmail